27 Multiple Myeloma Clinical Trials in San Francisco, CA (2026)

Q: How do I join a clinical trial in San Francisco?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you.

Recruiting Multiple Myeloma Studies in San Francisco

NCT00904878Recruiting

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other...

San Francisco, CA1,500 participantsUniversity of California, San Francisco

View Study Details

NCT06365060Recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is o...

San Francisco, CA400 participantsTufts Medical Center

View Study Details

NCT07258511Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody....

San Francisco, CAPHASE3400 participantsJanssen Research & Development, LLC

View Study Details

NCT05201781Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-te...

San Francisco, CAPHASE4295 participantsJanssen Research & Development, LLC

View Study Details

NCT06858579Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP)....

San Francisco, CAPHASE3256 participantsDianthus Therapeutics

View Study Details

NCT05850234Recruiting

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma....

San Francisco, CAPHASE1232 participantsAstraZeneca

View Study Details

NCT06297226Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma....

San Francisco, CAPHASE2230 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06500884Recruiting

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preven...

San Francisco, CAPHASE2210 participantsJanssen Research & Development, LLC

View Study Details

NCT06153251Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

San Francisco, CAPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT05652335Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and to...

San Francisco, CAPHASE1180 participantsJanssen Research & Development, LLC

View Study Details

NCT07116616Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM)....

San Francisco, CAPHASE1166 participantsModernaTX, Inc.

View Study Details

NCT05651932Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent...

San Francisco, CAPHASE1165 participantsK36 Therapeutics, Inc.

View Study Details

NCT07032662Recruiting

IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP....

San Francisco, CAPHASE2162 participantsImmunovant Sciences GmbH

View Study Details

NCT07266441Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells c...

San Francisco, CAPHASE2157 participantsJanssen Research & Development, LLC

View Study Details

NCT04844606Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks ...

San Francisco, CAPHASE3150 participantsEli Lilly and Company

View Study Details

NCT07096778Recruiting

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come b...

San Francisco, CAPHASE2100 participantsCellCentric Ltd.

View Study Details

NCT07219043Recruiting

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and later developed a condition called microvascular inflammation (MVI). MVI ...

San Francisco, CAPHASE281 participantsBiogen

View Study Details

NCT07075185Recruiting

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma....

San Francisco, CAPHASE170 participantsKelonia Therapeutics, Inc.

View Study Details

NCT07149857Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of whit...

San Francisco, CAPHASE260 participantsJanssen Research & Development, LLC

View Study Details

NCT05787574Recruiting

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD)...

San Francisco, CAPHASE239 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT04925375Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promis...

San Francisco, CAPHASE238 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT06798012Recruiting

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over...

San Francisco, CAPHASE236 participantsTakeda

View Study Details

NCT06348108Recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back a...

San Francisco, CAPHASE132 participantsAlfred Chung, MD

View Study Details

NCT06538064Recruiting

A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

The main aims of this study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why they changed to HyQvia from another therap...

San Francisco, CA30 participantsTakeda

View Study Details

NCT07665307Recruiting

Delayed Toxicities Post-CAR-T

This is an observational umbrella protocol evaluating toxicities after CAR-T therapy with ciltacabtagene autoleucel (cilta-cel) for RRMM, with a goal to identify key inflammatory features contributing...

San Francisco, CA30 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT03538899Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

This study aims to determine if a new method can be used to treat Artemis-deficient Severe Combined Immunodeficiency (ART-SCID), a severe form of primary immunodeficiency caused by mutations in the DC...

San Francisco, CAPHASE124 participantsUniversity of California, San Francisco

View Study Details

NCT05892393Recruiting

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]...

San Francisco, CAPHASE120 participantsRobert Flavell, MD, PhD

View Study Details

About Multiple Myeloma Clinical Trials in San Francisco

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 27 multiple myeloma clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 5,250 participants. Research is being sponsored by University of California, San Francisco, Tufts Medical Center, Janssen Research & Development, LLC and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in San Francisco — FAQ

Are there multiple myeloma clinical trials in San Francisco?

Yes, there are 27 multiple myeloma clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 27 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated September 1, 2026 from ClinicalTrials.gov